03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Diabetes
Martin Holst Lange: no photograph is held, so the academic plate is shown instead.
Academic
Martin Holst Lange
Chief Scientific Officer
1
0
0
0
0
0
0
0
Apr 2026MayJuneJulyAugSeptOctNovto date
1
press citation on 1 topic since 23 Apr 2026 · last quoted 25 Sept 2026
02 Quoted on · 1 of 29 topics
Martin Holst Lange: key facts
- Kind of voice
- Academic
- Role
- Chief Scientific Officer
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 25 Sept 2026
- First quoted
- 23 Apr 2026
04 On the record · press
What Martin Holst Lange has said
By outlet · linked articles
- blockonomi.com1
Where Martin Holst Lange has been quoted
- 01Novo Nordisk (NVO) Stock Rises After Pediatric Diabetes Drug Trial Success - Blockonomiblockonomi.com · 23 Apr 2026
Verbatim
“Oral semaglutide is an effective treatment option for children and adolescents with Type 2 diabetes who require glycaemic control beyond that provided by the current standard of care”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.